A Bird in the Hand
The bottom line on Chiron’s offer, said Viagene CEO Bob Abbott, was that, from a shareholder point of view, a bird in the hand was worth two in the bush.
You may also be interested in...
GSK achieved a first-in-class market oncology launch in 2020, but will have to increase that hit rate in order to fulfil its blockbuster ambitions.
The two companies can now market their HER-2 targeting antibody-drug conjugate in its second tumor type as they look to expand beyond breast cancer.